Oncology & Immuno-Oncology

Driving the next wave of immunotherapies addressing unmet needs by enhancing and leveraging activities of T, NK & Myeloid cells using various modalities ​

Our focuses include:

• Novel checkpoint inhibitor approaches
• Tumor targeted TNFR agonism
• Targeting immunosuppressive mediators within tumor microenvironment (e.g., adenosine pathway)
• Exploring new modalities to overcome resistance to current immunotherapy approaches in cancer

Meet the team

Enabling precision cancer therapy and rational combinations through collaborative translational and biomarker research.

We enable cancer precision medicine through forward and reverse translation approaches by:

• Delivering mature protein-, RNA- and immunohistochemistry-based biomarker assays
• Exploring novel technologies such as single-cell and spatial profiling
• Using computational tools to gain insights from preclinical and patient data sets
• Characterizing the effects of non-IO pipeline candidates on immune cells and the tumor microenvironment
• Leveraging molecular and cellular profiles from patient tumors to enhance and propose novel therapeutic concepts and combinations
• Leading Biomarker subteams within project teams

Meet the team

Delivering state-of-the-art in vivo pharmacology packages to support the success of our new anti-cancer therapies.

• We employ state-of-the-art in vivo models of cancer in testing our novel drug candidates that target tumor cells; These include the use of tumor models, human cell lines, and patient-derived xenografts (PDX).
• We use these models to demonstrate pharmacokinetic/pharmacodynamic (PK/PD) relationships and anti-tumor efficacy of our drug candidates.
• With our data and expertise, we support projects along the drug pipeline value chain – ranging from concept generation to launch. As part of project teams, we work to bring our drug candidates to patients by helping to identify sensitive cancer indications, drug combination partners and biomarkers.

Meet the team

Genomic instability (GI) is a hallmark of cancer

• GI is the result of mutations or other defects in components of the DNA Damage Response (DDR)
• Our strategy is to exploit these vulnerabilities and inhibit functionally redundant/essential factors of the DDR following the concept of synthetic lethality

Our key activities include

• Exploring the clinical efficacy and safety of our DDR kinase inhibitors targeting ATR, ATM, and DNA-PK
• Discovering first-in-class modulators of next-generation DDR targets (nucleases, helicases, polymerases)
• Evaluate attractive concepts in DDR field